First-pass extracted concept

PSMA4

Candidate: concept label1 source documents5 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

PSMA4 is presented as a prioritized druggable target candidate for hidradenitis suppurativa based on integrated MR, colocalization, transcriptomic, and single-cell analyses.

Source 1DOI PubMed

What problem it solves

It helps nominate a genetically and transcriptomically supported therapeutic target in a disease with limited treatment options and frequent drug resistance.

Source 1DOI PubMed

What it does not solve

The abstract does not show that targeting PSMA4 has yet been converted into a working therapy or direct intervention.

Source 1DOI PubMed

Alternatives

The same study also prioritizes MAST3 as another promising druggable target for HS.

Source 1DOI PubMed

Evidence Snippets

Colocalization analysis further prioritized PSMA4 and MAST3 as the most promising druggable targets for HS.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 5 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1cell type specificitysupports2026Source 1DOI PubMed

Single-cell analysis indicated that PSMA4 is predominantly enriched in CD4+ T cells and is involved in pro-inflammatory signaling, particularly the TNF pathway, in hidradenitis suppurativa.

Quoted textsource-backed

Further single-cell analysis revealed that PSMA4 was predominantly enriched in CD4+ T cells and involved in pro-inflammatory signaling, particularly the tumor necrosis factor (TNF) pathway.

Claim 2genetic associationsupports2026Source 1DOI PubMed

PSMA4 showed a strong positive statistical association with hidradenitis suppurativa in Mendelian randomization and colocalization analyses.

Quoted textsource-backed

PSMA4 (single nucleotide polymorphisms [SNPs] = 10; inverse-variance weighted [IVW] OR = 1.912, 95% CI: 1.492-2.450, <i>p</i> < 0.001; PP.H4 = 0.975)

Claim 3mechanistic hypothesissupports2026Source 1DOI PubMed

PSMA4 may promote inflammation through CD4+ T cell-mediated signaling in hidradenitis suppurativa.

Quoted textsource-backed

PSMA4 may promote inflammation via CD4+ T cell-mediated signaling, offering a novel avenue for treatment development.

Claim 4target prioritizationsupports2026Source 1DOI PubMed

PSMA4 and MAST3 were prioritized as promising druggable targets for hidradenitis suppurativa by integrated Mendelian randomization and colocalization analyses.

Quoted textsource-backed

Colocalization analysis further prioritized PSMA4 and MAST3 as the most promising druggable targets for HS.

Claim 5transcriptomic observationsupports2026Source 1DOI PubMed

Transcriptomic validation showed that PSMA4 is upregulated and MAST3 is downregulated in hidradenitis suppurativa lesions.

Quoted textsource-backed

Transcriptomic validation revealed that PSMA4 was upregulated and MAST3 was downregulated in HS lesions.